Holen Sie sich die Stockscreener-App
8.92
1.55%
-0.14
Vorhandelsmarkt:
8.82
-0.10
-1.12%
Schlusskurs vom Vortag:
$9.06
Offen:
$9.09
24-Stunden-Volumen:
3.58M
Relative Volume:
0.70
Marktkapitalisierung:
$2.27B
Einnahmen:
$885.72M
Nettoeinkommen (Verlust:
$-457.98M
KGV:
-5.0211
EPS:
-1.7765
Netto-Cashflow:
$293.05M
1W Leistung:
+7.08%
1M Leistung:
-1.11%
6M Leistung:
+19.41%
1J Leistung:
-13.31%
1-Tages-Spanne:
$8.795
$9.18
1-Wochen-Bereich:
$8.10
$9.18
52-Wochen-Spanne:
$6.00
$10.32
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.92 | 2.30B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
15.66 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.09 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.27 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Fortgesetzt | Evercore ISI | Outperform |
| 2025-10-15 | Fortgesetzt | TD Cowen | Buy |
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BIOCRYST (BCRX) director Jill Milne granted RSUs and options in board compensation - Stock Titan
BioCryst (BCRX) director receives stock grants and options, updates trust holdings - Stock Titan
BioCryst (BCRX) director receives RSU and option grants under board plan - Stock Titan
BioCryst (BCRX) director Steven Frank awarded RSUs and stock options - Stock Titan
BioCryst (NASDAQ: BCRX) director awarded RSUs and stock options as compensation - Stock Titan
BioCryst (BCRX) director Vincent Milano receives stock and option grants - Stock Titan
BioCryst (BCRX) director receives stock units and options grants - Stock Titan
Biocryst (NASDAQ: BCRX) director receives stock units and options grant - Stock Titan
Biocryst (BCRX) grants Theresa Heggie RSUs and stock options as board pay - Stock Titan
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up (BCRX) - Seeking Alpha
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (NASDAQ: BCRX) investors approve 7M-share stock incentive plan - Stock Titan
Sector Update: Healthcare Stocks Advance Pre-Bell Friday - Moomoo
BioCryst Advances HAE Treatments with New Clinical Data (BCRX) - GuruFocus
BioCryst highlights efficacy gains across hereditary angioedema portfolio - grafa.com
BioCryst presents new data on HAE therapies at EAACI meeting - Investing.com
BioCryst presents new data on HAE therapies at EAACI meeting By Investing.com - Investing.com Canada
Oral HAE drug reduces child attacks; new antibody data across patient subgroups - Stock Titan
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Yahoo Finance
BioCryst Pharmaceuticals Grants Stock Options and RSUs to New Employees - Quiver Quantitative
Nine new BioCryst hires receive stock options, RSUs as inducement - Stock Titan
How Biocryst Pharmaceuticals Inc. (BCRX) Affects Rotational Strategy Timing - Stock Traders Daily
Do BioCryst’s EAACI 2026 HAE Data Plans Subtly Recast the BCRX Long-Term Innovation Story? - Sahm
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances - MarketBeat
BCRX Technical Analysis | Trend, Signals & Chart Patterns | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
Earnings call transcript: BioCryst Q1 2026: EPS Miss, Revenue Beat - Investing.com
BCRX: ORLADEYO and navenibart drive rare disease growth, with key milestones and profitability ahead - TradingView
BIOCRYST (BCRX) Board Chair Vincent Milano receives stock grant as retainer pay - Stock Titan
BioCryst (BCRX) director awarded stock in lieu of cash retainer - Stock Titan
BioCryst (BCRX) director Jill C. Milne receives 1,262-share stock grant as board retainer - Stock Titan
Biocryst (BCRX) director takes share grant instead of cash fee - Stock Titan
BIOCRYST (BCRX) director Steven Frank granted 1,262 shares instead of $11,250 cash - Stock Titan
These 10 mid-cap U.S. healthcare companies rank among the market's most attractively valued stocks - Seeking Alpha
Could BioCryst (BCRX) HAE Data at EAACI Quietly Redefine Its Core Investment Story? - Sahm
(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Mixed Returns Temper Its Rare Disease Upside Narrative - Sahm
New ORLADEYO HAE data in children, adults to debut in Istanbul - Stock Titan
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewswire
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth from pediatric expansion - Investing.com Nigeria
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm
BCRX Should I Buy - Intellectia AI
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
BioCryst director Amy McKee sells $100,284 in company shares - Investing.com UK
BioCryst director Amy McKee sells $100,284 in company shares By Investing.com - Investing.com South Africa
Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97 - Stock Titan
Biocryst’s BCX-17725 as new approach for Netherton syndrome - BioWorld News
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - Yahoo Finance
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):